Search PubMed⌕ Search

Biomedical subjects

F Doutremepuich

Publications and source records attributed to F Doutremepuich.

At least 37 records · Page 2Linked to original sources
PubMed1995

[Experimental models of arterial thrombosis].

Arterial thrombosis is clearly responsible for a very wide range of cardiovascular diseases, which is why many models of arterial thrombosis have been developed. These models are based on various techniques such as electrical, mechanical, biochemical, photochemical induction. They are an essential prerequisite to the understanding of molecular and cellular phenomena and are also essential to test the antithrombotic activity of new molecules before the first clinical trials in man. The large range of models means that the most appropriate model can be selected for the study of the test substance. However, the antithrombotic activity of a substance needs to be studied by several models. Most of these models induce total occlusion in which the number of parameters studied is limited. As a result of technological progress and the development of techniques such as laser and image analysers, new perspectives are now available for both basic and pharmacological research. Consequently, the already major value for these models should continue to grow over the years to come.

Animals↗
PubMed1993

Influence of heparin on the chemotactic activity of human thrombin.

Chemoattractant properties of human thrombin have been studied, by polymorphonuclear leucocyte migration under agarose gel, in the presence of various sulphated macromolecules such as standard heparins, low molecular weight heparins, CY216, K2165, PK10169 and pentosane polysulphate. These compounds did not attract polymorphonuclear leucocytes within the range of concentrations used, whilst thrombin alone is a cytotaxin for these cells. Addition of heparins to thrombin led to an increase in the chemoattractant activity of this enzyme for at least one of the doses studied. Augmentation of the chemoattractant activity of thrombin by heparins was shown at concentrations equivalent to those found in-vivo after administration of therapeutic doses of heparin. Pentosane polysulphate, at the studied concentrations, did not lead to a significant rise in the chemoattractant activity of thrombin.

Chemotaxis, Leukocyte↗
PubMed1993

Effects of aspirin on embolization in an arterial model of laser-induced thrombus formation.

This model of arterial thrombosis induced by laser was used to evaluate the effect of aspirin (Aspegic) on embolization. A partial occlusion was induced in small mesenteric arterioles (diameter 35-40 microns) with an Argon Laser. The laser induced the formation of a vessel wall lesion with damage of endothelial cells. Thrombus formed within seconds after the laser lesion and grew rapidly. Embolization began within the minute following the laser flash. Thrombus formation and embolization were repetitive phenomena. The duration of embolization was 6.50 +/- 0.84 min in the control group. Then the thrombus became stable and partially obstructed the vessel lumen. The administration of aspirin at three doses (50, 100, 200 mg/kg) by intramuscular injection, 15 min before the laser injury, induced three different phenomena: (1) an increase of the number of laser injuries required for the thrombus formation; (2) a dose-dependent decrease in the duration of embolization, and (3) a dose-dependent decrease in the number of emboli. The highest dose injected induced the strongest reduction in the duration of embolization and the number of emboli.

Animals↗
PubMed1992

Effects of aprotinin on heparin activities and heparin neutralization with protamine.

In order to investigate the new situation in which aprotinin is proposed as a novel approach to reducing post operative bleeding, specially in cardiopulmonary bypass (CPB) surgery during which heparin and protamine are commonly used, preliminary in vitro and in vivo studies have been performed. Aprotinin increases the anticoagulant heparin effects in vitro, and the hemorrhage time in vivo. But in addition to protamine, there are no statistically significant differences with heparin-protamine situation, indicating aprotinin does not disturb the neutralizing activities of protamine on heparin.

Animals↗
PubMed1992

Could non steroidal anti-inflammatory drugs be used to potentiate L.M.W.H. activity in thrombosis? (Part II).

Thromboembolic diseases are one of the main cause of mortality. Heparin fractions obtained by chemical or enzymatical depolymerization of unfractionated heparin are now widely used in the prevention of those illness. However, curative dosages have bad side effects which could be avoid by the potentiation of the antithrombotic efficacy of non-active dosages. A previous study (4) has shown that a non-steroidal anti-inflammatory (NSAI) drug like Phenylbutazone could favour the antithrombotic efficacy of Fraxiparine at a very low dose. The aim of this study was then to determine if other NSAI elements could present the same or better proactive effects.

Animals↗
PubMed1992

The role of essential vitamins in the development of thrombosis and hemorrhage--an experimental study.

To evaluate the action of essential vitamins on hemorrhage, coagulation and thrombosis, a multivitaminized solution was daily administered at three different doses for two weeks to male Wistar rats. Two experimental models were carried out: a venous thrombosis and an induced-hemorrhage model. Results indicate a low thrombogenic effect, a large and dose-dependent decrease of hemorrhage and no effect on coagulation. The observed effects on thrombosis and hemorrhage were not connected with an overdose of vitamins involving many secondary effects, since no blood viscosity parameters were modified. Three main hypotheses are envisaged to explain these results: a direct effect on platelet functions, an action on the leukocytic population, and a possible modification of the vessel wall response. However, further investigations are needed to specify the mechanisms involved.

Animals↗
PubMed1991

Could non steroidal anti-inflammatory drugs be used to potentiate L.M.W.H activity in thrombosis? (Part I).

Heparin fractions are antithrombotic drugs prescribed for preventive treatment but their efficacy must be optimized to permit curative use without side effects. The present study was performed on 144 rats receiving a low molecular weight heparin (L.M.W.H), Fraxiparine, and a non steroidal anti-inflammatory drug (Phenylbutazone), which were injected simultaneously or separately. Neither Phenylbutazone nor L.M.W.H at their lowest dose (1 mg/kg) reduced thrombus size. However, administered together, they produced a significant limitation of thrombus growth. Variation in anti Xa activity limitation was only observed with the highest dose of Fraxiparine alone or in combination with Phenylbutazone (1 mg/kg) corresponding to its antithrombotic effect.

Animals↗
PubMed1991

Comparative study of three recombinant hirudins with heparin in an experimental venous thrombosis model.

Three recombinant hirudins (r-hirudins) produced by genetic processes from Escherichia coli and yeast were studied. r-Hirudins could be an alternative treatment to heparin; so, the antithrombotic activity of these drugs should be compared to heparin, the reference substance, in an experimental venous thrombosis model. In this model, the effect of these r-hirudins on thrombus weight reduction were not identical. They varied depending on the original product (E. coli or yeast). The growth-inhibiting activity of r-hirudins on existing thrombi is not dose dependent, whereas that of heparin is. Moreover, in the conditions of this study, higher doses of heparin, but not of hirudins, increased the bleeding time. Although hirudin has limited applications for the time being, it seems an interesting anticoagulant drug, and the availability of r-hirudin opens new therapeutic anticoagulation perspectives.

Animals↗
PubMed1990

Localization of the structural domain responsible for the chemotactic properties of thrombin on polymorphonuclear leukocytes.

Human alpha thrombin at 1.1.10(-5) M is chemotactic for human polymorphonuclear leukocytes. This thrombin property disappears when the alpha thrombin (1.1.10(-5) M) hirudin (1.32.10(-5) M) mixture is realized. The same result is obtained when the thrombin at 1.1. 10(-5) M is inhibited by antithrombin III in a ratio of 1 mol of thrombin for 4.5 mol of antithrombin III. The hirudin and the antithrombin III appear therefore to mask, by their binding the structural domain responsible for the chemotactic properties of thrombin on polymorphonuclear leukocytes.

Antithrombin III↗
PubMed1990

Coagulation impact on chemotactic activity generation for polymorphonuclear leukocytes.

Chemotactic technique in agarose gel has exposed the attractive properties of human alpha thrombin with respect to human polymorphonuclear leukocytes. The observed chemotaxis is maximal between 1.4.10-5 M and 1.6.10-5 M but extends from 2.8.10-6 M to 2.2.10-5 M. Human prothrombin, in an identical concentration zone as that studied for thrombin shows no chemotactic activity on the polymorphonuclear leukocytes. During coagulation the formed alpha thrombin attracts the polymorphonuclear leukocytes to it's formation site.

Chemotactic Factors↗
PubMed1990

Modifications of biological activities of heparin and fraxiparine induced by the size and the age of a thrombus. Experimental study.

Heparin and its fractions have often been tested on fresh experimental thrombosis. However in human clinic, drugs are administered not on fresh, but rather on old constituted thrombi. In order to evaluate the effects of antithrombotic agents in these conditions, both drugs (unfractionated heparin and Fraxiparine) were administered on 150 rats at different times and so, could take effect on thrombi with different ages. Heparin was more active as its fraction on fresh thrombi (2 hours old), but no more effects could be observed for all drugs when the thrombus was 52 hours old. Biological activities (A.P.T.T., anti-IIa and anti-Xa activities) decreased as the thrombi increased in weight and age.

Animals↗
PubMed1990

[How to standardize low molecular weight heparins].

Heparin, used in anticoagulant and antithrombotic therapeutic for over fifty years, turns out to mean important side effects and serious haemorrhagic risk. The obtaining, from 1976, of the first low molecular weight heparins (LMWH) preparations is partly allowed to overcome those problems. The LMWH present an identical or greater antithrombotic capacity than the unfractioned heparin and mean a lower haemorrhagic risk. Thus their use in antithrombotic therapy is very interesting. However, the existence of different units for the LMWH sets a standardization problem for their clinical use and for their biological follow up. The first international LMWH standard introduction by the World Health Organisation in 1986 may be useful to give a great homogeneity of the interlaboratory results, to serve as reference to the biologists, as activity standardization for the manufacturers or as security for the clinicians. However, it seems its definition mode and its validity call into question by several authors. The anti Xa activity, advocated in the biological surveillance, does not seem to perfectly fit to the LMWH therapy. The debate about the standardization of the low molecular weight heparins keeps open.

Heparin, Low-Molecular-Weight↗
PubMed1989

Could thrombus age be a modulator of heparin or L.M.W.H. activities?

The main thrombotic diseases are caused by old constituted thrombi. However, experiments to demonstrate the effects of heparin or heparin fragments on tPA release have been on fresh thrombi. This study on thrombi induced 6, 24, 48 or 72 hours before sampling shows variations in the main biological activities of both heparin and heparin fragment (CY222) as the thrombus ages. This effect is particularly observed on tPA release which is statistically reduced (p less than 0.001). Thrombus age seems to be a modulator of heparin and heparin fragment biological activities.

Animals↗
PubMed1989

[Low molecular weight heparins].

The apparition in the 80's of low molecular weight heparins (LMWHs) obtained by chemical or enzymatical splitting, modified the fields of prophylactic treatment of thromboembolic diseases. These drugs present on heparin numerous advantages: equal antithrombotic activity with a smaller bleeding risk, higher bioavailability, longer pharmacokinetic, which simplify their use. The definite mode of action remains unknown, but LMWH act at different steps like coagulation (by AT III), fibrinolysis, blood cells, endothelial cells. Further, like heparin, they can be neutralized by protamine. However the right, simple, specific biological assay which presents a good correlation with the antithrombotic activity, remained to be established.

Heparin, Low-Molecular-Weight↗